Multiple sclerosis (MS) is a disease of the brain and spinal cord in which the body’s immune system attacks its own tissues (an autoimmune disease) that affects more than 400,000 Americans. With MS, the immune systems mistakes the protective covering on the nerve fibers (myelin sheath) as a foreign invader and therefore attacks it. An over-active immune response and inflammation leads to lesions in the brain and spinal cord.
These lesions cause communication problems (they can delay or block communication of messages) between the brain and spinal cord with other parts of the body.
Common Symptoms of MS: numbness, pain, tingling, vision problems, the feeling of brain “fogginess,” spasticity and tightness, imbalance, extreme fatigue, depression and numbness or tingling in the extremities, among other issues. Some patients may develop problems walking and my need assistance.
MS can also frequently cause forgetfulness or difficulty concentrating as well as problems with bladder and bowel functions (More Information). The changes that MS brings can be life-altering, affecting both quality of life and relationships with others.
Low Dose Naltrexone (LDN)
Read about the mechanism in which low dose naltrexone LDN works to reduce inflammation.
Abstract Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone’s better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.
What is Low Dose Naltrexone (LDN)?
Naltrexone belongs to a class of drugs known as opioid antagonists. Naltrexone blocks opiate drugs from binding to the opioid receptors, which can result in increased endorphin and enkephalin release. Therefore, this results in reduced: 1. signaling and release of inflammatory substances, 2. nerve cell inflammation and 3. autoimmune mediators.